Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$105,000.00
Development and therapeutic application of a novel chimpanzee adenovirus-based vaccine against pulmonary tuberculosis
FY 2015-16
Summary
Tuberculosis (TB) is an ancient disease that continues to claim millions of lives every single year. As such, rigorous antibiotic therapy regimens have remained the primary strategy in combating this disease. Unfortunately, a majority of individuals prematurely stop antibiotic therapy due to the complexity, duration, and toxic side effects associated with such regimens. This poor, fragmented patient adherence not only leads to rapid disease relapse and reduced life quality, but also represents a global threat as it heavily contributes to the emergence of antibiotic-resistant TB. As such, there is a critical need for novel strategies which enhance patient adherence in order to improve treatment outcome and curb the emergence of drug resistance. Therapeutic vaccines represent such a strategy, designed to complement antibiotic therapy through bolstering an individual's anti-TB immune responses in order to accelerate disease clearance. Within our lab we have developed a novel, highly efficacious viral-based TB vaccine which we have now begun to test therapeutically. Through boosting an individual's anti-TB immune responses, our vaccine aims to accelerate the treatment of TB in comparison to conventional antibiotic therapy alone, and ultimately reduce the duration of antibiotics needed for successful disease treatment. Ultimately, our therapeutic vaccine has the capacity to revolutionize how TB is treated clinically through improving patient adherence, reducing disease relapse, and preventing the deadly emergence of drug resistant disease.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
347954
Name
Afkhami Sam
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Development and therapeutic application of a novel chimpanzee adenovirus-based vaccine against pulmonary tuberculosis
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Biohazard Containment Level 3; Flow Cytometry; Immunology; Infectious Diseases; Molecular Biology; Recombinant Vaccines; Therapeutics; Tuberculosis
Abstract
Tuberculosis (TB) is an ancient disease that continues to claim millions of lives every single year. As such, rigorous antibiotic therapy regimens have remained the primary strategy in combating this disease. Unfortunately, a majority of individuals prematurely stop antibiotic therapy due to the complexity, duration, and toxic side effects associated with such regimens. This poor, fragmented patient adherence not only leads to rapid disease relapse and reduced life quality, but also represents a global threat as it heavily contributes to the emergence of antibiotic-resistant TB. As such, there is a critical need for novel strategies which enhance patient adherence in order to improve treatment outcome and curb the emergence of drug resistance. Therapeutic vaccines represent such a strategy, designed to complement antibiotic therapy through bolstering an individual's anti-TB immune responses in order to accelerate disease clearance. Within our lab we have developed a novel, highly efficacious viral-based TB vaccine which we have now begun to test therapeutically. Through boosting an individual's anti-TB immune responses, our vaccine aims to accelerate the treatment of TB in comparison to conventional antibiotic therapy alone, and ultimately reduce the duration of antibiotics needed for successful disease treatment. Ultimately, our therapeutic vaccine has the capacity to revolutionize how TB is treated clinically through improving patient adherence, reducing disease relapse, and preventing the deadly emergence of drug resistant disease.
Competitiondate
201510
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Afkhami, Sam
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~